Non-Invasive Prenatal Testing (NIPT) screens for chromosomal abnormalities using foetal DNA in the mother’s bloodstream. Performed from 10 weeks, no risk to mother or baby.
What Does NIPT Screen For?
Trisomy 21 (Down’s syndrome), Trisomy 18 (Edwards’ syndrome), Trisomy 13 (Patau’s syndrome), sex chromosome abnormalities, and — with extended panels — microdeletions.
Who Should Consider NIPT?
Women aged 35+, personal or family history of chromosomal conditions, pregnancies following IVF, abnormal first trimester combined screening result.
Accuracy
Detection rate over 99% for Trisomy 21. NIPT is a screening test — positive results require confirmatory diagnostic testing (CVS or amniocentesis).
The Process
Simple maternal blood draw. Results typically available within 7–10 working days.
To arrange NIPT as part of your antenatal care with Assist. Prof. Dr. Muzaffer Uçarer, contact UCARER Women’s Health.
Prices
- €375
Our medical prices are fixed; your exact, all-inclusive price is confirmed in writing after your consultation. See our full price list →
Fetal anomaly screening at UCARER, Bahçeşehir: our approach
At UCARER Women’s Health in Bahçeşehir (Başakşehir), Istanbul, fetal anomaly screening is a structured, non-invasive protocol offered to every pregnancy, overseen by two experienced obstetrician–gynaecologists, Assist. Prof. Dr. Muzaffer Uçarer and Op. Dr. Meryem Gökkaya Uçarer. The protocol combines:
- The first-trimester combined (“dual”) test — a blood test plus nuchal translucency ultrasound, usually between weeks 11 and 14.
- NIPT (non-invasive prenatal testing) — a maternal blood test that assesses the risk of common chromosomal conditions with high accuracy and no risk to the baby.
- Around the 20th week, a detailed fetal anomaly ultrasound that examines the baby’s anatomy in detail, together with a perinatology consultation from a professor-level perinatology specialist for every patient.
NIPT and the combined test — how they differ
The combined (dual) test estimates risk from ultrasound and blood markers; NIPT analyses cell-free fetal DNA in the mother’s blood and gives a more precise risk assessment for conditions such as Down syndrome. Both are screening tests: when a result indicates higher risk, your obstetrician discusses the next steps with you. If a pregnancy needs closer follow-up, see our high-risk pregnancy care.
Frequently asked questions
Is NIPT safe for the baby? Yes. NIPT is a simple maternal blood test and carries no risk to the baby.
What is the difference between NIPT and the dual test? The dual test combines ultrasound and blood markers to estimate risk in the first trimester; NIPT analyses fetal DNA in the mother’s blood for a more precise risk assessment. Your obstetrician advises which is appropriate for you.
When is the detailed anomaly scan done? Around the 20th week; at UCARER it is offered to every patient together with a perinatology consultation from a professor-level specialist.
Do these tests diagnose a condition? They are screening tests that assess risk. If risk is higher, your obstetrician will discuss further diagnostic options with you.
Contact UCARER Women’s Health to book your consultation with Assist. Prof. Dr. Muzaffer Uçarer.